Document is current

Article History

Received: 7 March 2025

Revised: 9 April 2025

Accepted: 11 April 2025

First Online: 25 April 2025

Competing interests

: FHH served as an advisor for Novartis, CTI, BMS, Janssen, Abbvie, GSK, Merck and AOP and received research funding from Novartis, Celgene/BMS and CTI. J-JK reported receiving consulting fees from AbbVie, BMS, and Novartis; payment or honoraria for lectures, presentations, or educational events from AOP, BMS/Celgene, and Novartis; participated on a DSM Board or Advisory Board for Incyte. MZ has received honoraria from AstraZeneca, AbbVie, Roche, Eli-Lilly, Pfizer and Takeda, and has participated in advisory boards for AstraZeneca, AbbVie, Novartis, Eli-Lilly, Esai, Roche, Pfizer, Gilead Sciences, Janssen and BMS. JK has provided consultancy services for AbbVie, Astra, Beigene, BMS, Daichi, Incyte, Ipsen, Janssen, Lilly, MSD, Novartis, Oncopeptides, Pfizer, Roche, Sanofi and Takeda; has received honoraria from Beigene, BMS, Janssen and Roche and provided congress support for Beigene, Ipsen, Lilly, Octapharm and Roche. EG and SG are employees of Novartis. MG has provided consultancy services for, and received honoraria from AOP, Novartis, BMS, AbbVie, Roche, Janssen, Gilead Sciences, AstraZeneca, Sierra, Eli Lilly and GSK. These data were presented in part at the American Society of Hematology Congress in December 2022 (64th ASH Meeting; December 10–13, 2022; New Orleans, USA; Poster 3036). Novartis Inc. served as a sponsor and was involved in the design of the study.